The global cardiac mapping market is projected to grow at a CAGR of 12.93% to reach US$1,828.167million by 2027, from US$780.501 million in 2020.
Atrial fibrillation is a serious growing condition that affects the heart, and the major causes include an unhealthy lifestyle that many individuals lead. According to the American Heart Association, about 2.3 million people in the United States alone suffer from atrial fibrillation. This problem significantly increases the risk of having getting a stroke. Moreover, according to the statistical data provided by the NHS (National Health Service), arrhythmia is a problem that is also known as a heart rhythm problem and is approximately faced and experienced by more than 2 million people a year in the UK. The most common types of arrhythmia that people suffer from include atrial fibrillation, in which the heart beats at an irregular and faster than normal pace. One of the reasons that can result in atrial fibrillation is the consumption of high amounts of alcohol or unhealthy eating habits, such as a diet with high levels of fats and cholesterol, which tend to block the arteries. Therefore, these factors lead individuals to go for health checkups more often and opt for proper and effective heart health checkups or EP exams. This leads to an increase in the adoption of cardiac mapping products and devices, thereby augmenting the market growth over the forecast period.
New and E-effective techniques that can successfully treat atrial fibrillation are providing opportunities for the market players they can harness and boost their market position and accelerate market growth.
There are many advancements in and enhanced procures products and techniques coming up to treat the problem of atrial F fibrillation, which is a growing and persistent problem. In March 2020, a clinical trial that uses pulse-field energy to heal patients and poses a novel approach to treating this and achieving more desirable and accurate patient outcomes was published. The trial of this method was conducted by the Heart Rhythm Society (HRS) in 2020 and was also published in Circulation Arrhythmia and Electrophysiology. The test compared the tissue selectivity of the PFA technique over the Radon Frequency ablation (RF) technique. Therefore, groundbreaking tests and findings such as these provide the market players with an opportunity to enhance and upgrade their product lines by adding products catering to this method and contributing e to the market growth over the forecast period.
Cardiac Mapping Industry Product Offerings by Major Market Players in the Cardiac Mapping Market
Furthermore, the interest being shown by the market payers to provide the end-users such as hospitals and diagnostic centres ers with innovative and advanced cardiac mapping products fuels ing the market growth further over the forecast period
Some of the examples of product offerings are as follows:
Biotronik recently announced a collaboration with Acutus Medical to provide a comprehensive service portfolio of electrophysiology, mapping, ablation, and other accessory products to facilitate catheter-based treatment of cardiac arrhythmias. In May 2020, Biotronik announced that they have partnered up with Acutus Medical to provide a comprehensive service portfolio of electrophysiology, mapping, ablation, and some other accessory products to facilitate catheter-based treatment of cardiac arrhythmias. The product is being launched across the regional markets in Europe and Asia. Their product is called the “Acutus AcQMap System. This product is developed with multi-mode mapping capabilities and is a non-contact mapping stem that can facilitate the mapping of unstable and stable rhythms. In addition, it can optimize the treatment of different types of arrhythmia in under 3 minutes.
In October 2019, Baylis Medical, which is considered one of the leading manufacturing companies for cardiology devices to aid the physicians, announced the first use of its new product line called its product, “ EPstar Fixed Electrophysiology Catheters.”. “The product line includes the “2-French Electrophysiology Catheter”, the “6F guiding catheter” for allowing deeper coronary sinus mapping (CS mapping). Furthermore, the EPstar catheters can provide the smallest catheters available for diagnosis in the North American electrophysiology market, allowing physicians to perform the more effective cardiac mapping. In addition, the EPstar catheters can make available the smallest catheters available for the diagnosis available in the North American electrophysiology market, allowing the physicians to carry out more effective cardiac mapping.
The North American region is estimated to hold a significant market share due to the rising geriatric population over the forecast period. The Asia Pacific region is estimated to increase its market share due to the initiatives being taken to improve the medical and healthcare infrastructure of countries such as India.
The North American region is estimated to hold a significant share over the forecast period due to the well-established healthcare industry and the availability of quality healthcare services, coupled with the early adoption of advanced and enhanced medical devices and detection products, which are being made available the market players. In addition, the growing geriatric population and the increased risk posed by heart problems are among other reasons for the rising demand for cardiac mapping in countries such as the US.
The Asia Pacific region is estimated to increase its share over the forecast period due to the initiatives being taken and the investment being made to develop the medical infrastructure in countries such as India to provide better healthcare facilities available to the population.
The disease outbreak of COVID-19 drives the growth of the cardiac mapping market. Several research studies have been published to provide insight into the downside risk of the pandemic. A research project issued in January 2021 labelled "Cardiac Involvement of COVID-19: A Comprehensive Review" mentioned that COVID-19 can have a substantial impact on patients' cardiovascular systems. COVID-19 fatalities are strongly linked to cardiovascular disease, hypertension, and diabetes. As a result, patients with CVDs must take every precaution against COVID-19, which may necessitate the use of cardiac mapping. Likewise, another research project captioned "Impact of COVID-19 on the Cardiovascular System: A Review of Available Reports" released in October 2020 stated that there is an uptick in high mortality and morbidity suffering from both cardiovascular events and COVID-19. As a result, during treatment, more emphasis should be placed on viral infection-related heart problems. The market for such studies is expected to grow in the future as a result of the need for cardiac mapping as a result of the COVID-19 pandemic.
Recent Developments
January 2022, Medtronic plc, a leading global in healthcare technology, announced an agreement to procure Affera, Inc., a privately-held medical technology-based company in the Boston area. Affera develops and manufactures cardiac mapping and navigation systems.
January 2022, Abbott obtained FDA clearance for its EnSite X EP with EnSite Omnipolar technology. EnSite X EP generates intricate three-dimensional maps of the heart to assist physicians in identifying and treating areas of the heart where unusual rhythms originate.
| Report Metric | Details |
| Market size value in 2020 | US$780.501 million |
| Market size value in 2027 | US$1,828.167 million |
| Growth Rate | CAGR of 12.93% from 2020 to 2027 |
| Base year | 2020 |
| Forecast period | 2022–2027 |
| Forecast Unit (Value) | USD Million |
| Segments covered | Product, Indication, End-User, And Geography |
| Regions covered | North America, South America, Europe, Middle East and Africa, Asia Pacific |
| Companies covered | Biosense Webster, Inc., Medtronic, Abbott, BIOTRONIK SE & Co KG, Acutus Medical, Baylis Medical Company, Inc., Boston Scientific Corporation |
| Customization scope | Free report customization with purchase |
Segmentation:
Frequently Asked Questions (FAQs)
Q1. What will be the cardiac mapping market size by 2027?
A1. The global cardiac mapping market is projected to reach a market size of US$1,828.167 million by 2027.
Q2. What is the size of the global cardiac mapping market?
A2. Cardiac Mapping Market was valued at US$780.501 million in 2019.
Q3. What are the growth prospects for the cardiac mapping market?
A3. The cardiac mapping market is projected to grow at a CAGR of 12.93% over the forecast period.
Q4. How is the global cardiac mapping market segmented?
A4. The global cardiac mapping market has been segmented by product, indication, end-user, and geography.
Q5. Which region holds the largest market share in the cardiac mapping market?
A5. The North American region is estimated to hold a significant share in the global cardiac mapping market.
Biosense Webster, Inc.
Medtronic
Abbott
BIOTRONIK SE & Co KG
Acutus Medical
Baylis Medical Company, Inc.
Boston Scientific Corporation
All our studies come with 2 months of analyst support.
We are in compliance with the global privacy laws.